Literature DB >> 17716683

Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons.

Steven R Fauce1, Otto O Yang, Rita B Effros.   

Abstract

During HIV-1 infection, the CD8(+) T lymphocyte response is critical to controlling the virus; indeed, the development of AIDS results, in large part, from the eventual failure of this response. The ability to measure the composite CD8(+) T lymphocyte anti-viral activity is, therefore, an essential requirement in the evaluation of immune based therapies and potential vaccines. We report here the details of a reproducible assay that measures the ability of CD8(+) T lymphocytes to suppress viral production by infected autologous CD4(+) T lymphocytes. The assay is not limited to persons with any specific HLA type, and the use of bi-specific antibodies for cell expansion makes the assay feasible in situations where cell numbers may be limiting. The measurement of viral production over time provides a global readout of the CD8(+) T lymphocyte overall function against HIV-1, which can be used for longitudinal assessment of individual HIV-infected persons in order to evaluate therapy, immune reconstitution, and new vaccines.

Entities:  

Mesh:

Year:  2007        PMID: 17716683      PMCID: PMC2151928          DOI: 10.1016/j.jim.2007.07.017

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  26 in total

Review 1.  Tracking the killers: how should we measure CD8 T cells in HIV infection?

Authors:  Judy Lieberman
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

2.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Authors:  G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms.

Authors:  O O Yang; S A Kalams; A Trocha; H Cao; A Luster; R P Johnson; B D Walker
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents.

Authors:  C C Wilson; J T Wong; D D Girard; D P Merrill; M Dynan; D D An; S A Kalams; R P Johnson; M S Hirsch; R T D'Aquila
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

6.  Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis.

Authors:  R B Effros; R Allsopp; C P Chiu; M A Hausner; K Hirji; L Wang; C B Harley; B Villeponteau; M D West; J V Giorgi
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

7.  A reproducible method to detect CD8 T cell mediated inhibition of HIV production from naturally infected CD4 cells.

Authors:  M A Hausner; J V Giorgi; S Plaeger-Marshall
Journal:  J Immunol Methods       Date:  1993-01-04       Impact factor: 2.303

8.  HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication.

Authors:  C E Mackewicz; M R Garovoy; J A Levy
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Authors:  M R Klein; C A van Baalen; A M Holwerda; S R Kerkhof Garde; R J Bende; I P Keet; J K Eeftinck-Schattenkerk; A D Osterhaus; H Schuitemaker; F Miedema
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  15 in total

1.  In vitro sensitization of T cells with DC-associated/delivered HIV constructs can induce a polyfunctional CTL response, memory T-cell response, and virus suppression.

Authors:  Swarali Kurle; Madhuri Thakar; Ashwini Shete; Ramesh Paranjape
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

2.  Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.

Authors:  Kathryn E Stephenson; Hualin Li; Bruce D Walker; Nelson L Michael; Dan H Barouch
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

3.  Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells.

Authors:  Anita Parmigiani; Maria F Pallin; Helena Schmidtmayerova; Mathias G Lichtenheld; Savita Pahwa
Journal:  Hum Immunol       Date:  2010-10-25       Impact factor: 2.850

Review 4.  HIV vaccines: lessons learned and the way forward.

Authors:  Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 5.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

6.  Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes.

Authors:  Steven Russell Fauce; Beth D Jamieson; Allison C Chin; Ronald T Mitsuyasu; Stan T Parish; Hwee L Ng; Christina M Ramirez Kitchen; Otto O Yang; Calvin B Harley; Rita B Effros
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

7.  Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.

Authors:  Mark J Boaz; Peter Hayes; Tony Tarragona; Laura Seamons; Andrew Cooper; Josephine Birungi; Paul Kitandwe; Aloysius Semaganda; Pontiano Kaleebu; Gwynneth Stevens; Omu Anzala; Bashir Farah; Simon Ogola; Jackton Indangasi; Patrick Mhlanga; Melanie Van Eeden; Madhuri Thakar; Ashwini Pujari; Shadri Mishra; Nilu Goonetilleke; Stephen Moore; Abdul Mahmoud; Pattabiraman Sathyamoorthy; Jayashri Mahalingam; Paranji R Narayanan; Vadakkuppattu D Ramanathan; Josephine H Cox; Len Dally; Dilbinder K Gill; Jill Gilmour
Journal:  Clin Vaccine Immunol       Date:  2008-12-17

8.  Measuring inhibition of HIV replication by ex vivo CD8⁺ T cells.

Authors:  Chloe K Slichter; David P Friedrich; Rebecca J Smith; Paula N Walsh; Greg Mize; Julie L Czartoski; M Juliana McElrath; Nicole Frahm
Journal:  J Immunol Methods       Date:  2013-12-25       Impact factor: 2.303

9.  T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge.

Authors:  Mauricio A Martins; Nancy A Wilson; Jason S Reed; Chanook D Ahn; Yann C Klimentidis; David B Allison; David I Watkins
Journal:  J Virol       Date:  2010-02-17       Impact factor: 5.103

10.  Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses.

Authors:  Marloes A Naarding; Natalia Fernandez; John C Kappes; Peter Hayes; Tina Ahmed; Mert Icyuz; Tara G Edmonds; Philip Bergin; Omu Anzala; Tomas Hanke; Lorna Clark; Josephine H Cox; Emmanuel Cormier; Christina Ochsenbauer; Jill Gilmour
Journal:  J Immunol Methods       Date:  2013-11-28       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.